Graham Capital Management L.P. bought a new position in Qiagen (NYSE:QGEN – Get Rating) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 40,297 shares of the company’s stock, valued at approximately $1,974,000.
Other institutional investors also recently bought and sold shares of the company. Invesco Ltd. raised its holdings in Qiagen by 3.4% during the first quarter. Invesco Ltd. now owns 770,341 shares of the company’s stock valued at $37,747,000 after acquiring an additional 25,093 shares during the period. Achmea Investment Management B.V. bought a new stake in Qiagen during the first quarter valued at about $1,996,000. Renaissance Technologies LLC bought a new stake in Qiagen during the first quarter valued at about $13,000,000. Northern Trust Corp raised its holdings in Qiagen by 48.6% during the first quarter. Northern Trust Corp now owns 1,206,713 shares of the company’s stock valued at $59,129,000 after acquiring an additional 394,731 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Qiagen by 12.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 27,259 shares of the company’s stock valued at $1,336,000 after acquiring an additional 2,919 shares during the period. 55.65% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, StockNews.com lowered Qiagen from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 29th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $54.50.
Qiagen Trading Up 0.2 %
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
- Get a free copy of the StockNews.com research report on Qiagen (QGEN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.